MedTrace Logo

RWD Study in HER2+ mBC Patients in Third-Line Therapy

NCT04566458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2021-10-07

No results posted yet for this study

Summary

This retrospective observational study will collect Canadian real-world data (RWD) from HER2+ metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (OS), progression free survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources utilization (HRU) during third-line therapy.

Conditions

  • Breast Cancer Stage IV

Interventions

OTHER

No intervention

retrospective chart review study

Sponsors & Collaborators

  • Knight Therapeutics

    collaborator UNKNOWN

  • Exactis Innovation

    lead OTHER

Principal Investigators

  • Gerald Batist · Exactis Innovation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-05-30
Completion
2021-05-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566458 on ClinicalTrials.gov